بروكاييناميد
مراجع

↑  Shobha Phansalkar; Amrita A Desai; Douglas Bell; Eileen Yoshida; John Doole; Melissa Czochanski; Blackford Middleton; David W Bates (26 Apr 2012). "High-priority drug-drug interactions for use in electronic health records". Journal of the American Medical Informatics Association (بالإنجليزية). 19 (5): 735–743. DOI:10.1136/AMIAJNL-2011-000612. ISSN:1067-5027. PMC:3422823. PMID:22539083. QID:Q17505343.
↑  Osadchii، Oleg E. (23 يوليو 2013). "Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig". Fundamental & Clinical Pharmacology: 382.
↑  Zamponi، Gerald W. (1993). "Dual Actions of Procainamide on Batrachotoxin-activated Sodium Channels: Open Channel Block and Prevention of Inactivation". Biophysical Journal. ج. 65: 2333.
↑  Gould، ed. by Lawrence A. (1983). Drug treatment of cardiac arrhythmias. Mount Kisco: Futura Publishing Company. ص. 73–74. ISBN:0879931906. {{استشهاد بكتاب}}: |الأول1= باسم عام (مساعدة)
↑  Fenster، P.E.؛ Comess، K.A.؛ Marsh، R.؛ Katzenberg، C.؛ Hager، W.D. (1983). "Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion". American Heart Journal. ج. 106 ع. 3: 501–504. DOI:10.1016/0002-8703(83)90692-0. PMID:6881022.
↑  Jan Koch-Weser, MD; Stuart W. Klein, MD. Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects. doi:10.1001/jama.1971.03180220036006.
↑  Elliott M. Antman. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 4th Edition. (ردمك 978-1-4557-0101-8). P410
1 2  US Food and Drug Administration. "Drugs at FDA: FDA Approved Drug Products". USA: إدارة الغذاء والدواء (الولايات المتحدة) (FDA). مؤرشف من الأصل في 2006-07-20. اطلع عليه بتاريخ 2012-08-13.
↑  De la Horz D، Doctor BP، Ralston JS، Rush RS، Wolfe AD (21 يوليو 1986). "A simplified procedure for the purification of large quntities of fetal bovine serum acetylcholinesterase". Life Sci. ج. 39 ع. 3: 195–9. PMID:3736320. مؤرشف من الأصل في 2018-02-22.
↑  Ralston JS، Main AR، Kilpatrick BF، Chasson AL (1 أبريل 1983). "Use of procainamide gels in the purification of human and horse serum cholinesterases". Biochem J. ج. 211 ع. 1: 243–250. PMC:1154348. مؤرشف من الأصل في 2020-03-14.
↑  Saxena A، Luo C، Doctor BP (أكتوبر 2008). "Developing procedures for the large-scale purification of human serum butyrylcholinesterase". Protein Expr Purif. ج. 61 ع. 2: 191–6. DOI:10.1016/j.pep.2008.05.021. PMID:18602477. مؤرشف من الأصل في 2018-07-23.
1 2  Lawson، DH؛ Jick، H (أكتوبر 1977). "Adverse reactions to procainamide". British Journal of Clinical Pharmacology. ج. 4 ع. 5: 507–11. PMC:1429167. PMID:911600.
↑  Uetrecht, Jack, Nasir Zahid, and Robert Rubin. "Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes." Chemical research in toxicology 1.1 (1988): 74-78.
↑  Roberts, Stephen M., et al. "Procainamide hydroxylamine lymphocyte toxicity—I. Evidence for participation by hemoglobin". International journal of immunopharmacology 11.4 (1989): 419-427.
↑  Gay, Royal J., and David F. Brown. "Pacemaker failure due to procainamide toxicity". The American journal of cardiology 34.6 (1974): 728-732.
↑  Osadchii، Oleg E. (23 يوليو 2013). "Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig". Fundamental & Clinical Pharmacology: 382.
↑  Gould، Lawrence A. (ed.) (1983). Drug treatment of cardiac arrhythmias. ماونت كيسكو (نيويورك): Futura Publishing Company. ص. 74. ISBN:0879931906. {{استشهاد بكتاب}}: |الأول1= باسم عام (مساعدة)
↑  Zamponi, G.W., Sui, X., Codding, P.W., & French, R.J. (1993). "Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation". Biophys J 65(6): 2324-2334. doi: 10.1016/s0006-3495(93)81291-8
↑  Roden, Dan M., et al. "Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide". The American journal of cardiology 46.3 (1980): 463-468.
1 2  Uetrecht, J. P., Freeman, R. W., & Woosley, R. L. (1981). "The implications of procainamide metabolism to its induction of lupus". Arthritis Rheum 24(8), 994-1003.
1 2  DrugBank. Procainamide (2013, September 16) Retrieved March 27, 2015 from http://www.drugbank.ca/drugs/DB01035 نسخة محفوظة 2019-12-06 على موقع واي باك مشين.
↑  Adams HR. 1995. Drugs Acting on the Cardiovascular System. Veterinary Pharmacology and 	Therapeutics. Seventh Edition: 451-500
↑  Plumb DC. 1999. Veterinary Drug Handbook. PharmaVet Publishing. White Bear Lake (USA).
↑  ChEBI. procainamide (CHEBI:8428). (n.d.). Retrieved April 8, 2015 from http://www.ebi.ac.uk/chebi/searchFreeText.do?searchString=51-06-9 نسخة محفوظة 29 أغسطس 2021 على موقع واي باك مشين.
↑  DeRuiter J. 2005. "Amides and Related Functional Groups". Principles of Drug Action. 1
↑  Hollman A (فبراير 1992). "Procaine and procainamide". Br Heart J. ج. 67 ع. 2: 143. DOI:10.1136/hrt.67.2.143. PMC:1024743. PMID:18610401.
1 2  MJA Walker: "Antiarrhythmic drug research". Br J Pharmacol 2006;147;S222-S231. doi: 10.1038/sj.bjp.0706500
↑  Hollman A (February 1992). "Procaine and procainamide". Br Heart J 67(2): 143. doi:10.1136/hrt.67.2.143.
1 2  Moe GK, Abildskov 1A. "Antiarrhythmic drugs". In: Goodlan LS, Gilman A (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 3rd edition. New York: Macmillan; 1965. pp. 699-715.
1 2  "Historical development of antiarrhythmic drug therapy". In: Lüderitz B (ed). History of Disorders of Cardiac Rhythm. 3rd edition. New York; Wiley-Blackwell; 2002, pp. 87-114.
↑  "Center for Drug Evaluation and Research: Drug Approval Package" (PDF). FDA. مؤرشف من الأصل (PDF) في 2017-02-18.